Sultan M. Alshahrani

Fixed-Dose Combination of Dipeptidyl Peptidase-4 Inhibitors Plus Metformin in Patients with Type 2 Diabetes: A Review on Safety and Efficacy

Sultan M. Alshahrani, Hamed Ali Alshahrani, Saud Dhafer Alshahrani, Noura Mohammed Alabdulla, Yazeed Fahad Alshahrani, Abdulmohsen Nasser Alshahrani & Ali Mohammed Alshahrani · Journal of Pharmaceutical Research International · 2021

There is a significant increase noted in the incidence and prevalence of Type 2 diabetes mellitus (T2DM). The global number of diabetic patients is projected by the International Diabetes Federation (IDF) to reach 552 million. T2DM disease has chronic and progressive nature. More...

Open access Research Article 10.9734/jpri/2021/v33i53A33638

Should Travellers have Priorities for COVID 19 Vaccine?

Najim Z. Alshahrani, Sultan M. Alshahrani, Nada Fussi & Mohammed J. Alsheef · Journal of Pharmaceutical Research International · 2021

The “Type of Article” of this paper is “Letter to the Editor”. This paper discuses about: “Should Travellers have Priorities for COVID 19 Vaccine?”. No formal abstract is available. Readers are requested to read the full article.

Open access Research Article 10.9734/jpri/2020/v32i4731111

A Case Report of COVID-19 in Yemen: Detailed Clinical Observations

Khaled M. Alakhali, Sultan M. Alshahrani, Yaser Mohammed Al- Worafi & Lyna Irawati · Journal of Pharmaceutical Research International · 2020

Coronavirus (COVID-19) is an infectious disease caused by a newly discovered coronavirus. We reported a 59-year-old Yemeni physician who was treated at home with complaints of COVID-19 symptoms. After receiving the treatment according to the COVID-19 guidelines established in Yem...

Open access Research Article 10.9734/jpri/2020/v32i2630832